Cost-effectiveness of losartan in patients with hypertension and LVH in Spain: An economic evaluation based on the life trial

被引：1
|
作者：
Ruilope, LM
Burke, TA
Carides, GW
Nocea, G
机构：
[1] Hosp 12 Octubre, E-28041 Madrid, Spain
[2] Merck & Co Inc, Whitehouse Stn, NJ USA
[3] Merck Res Labs, Blue Bell, PA USA
[4] MSD Spain, Madrid, Spain
来源：
VALUE IN HEALTH | 2004年 / 7卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)65797-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：689 / 689
页数：1
相关论文
共 50 条
  • [41] Economic evaluation of losartan compared with atenolol in the treatment of hypertension with left ventricular hypertrophy: A cost-minimization analyisis based on life study
    Chevreul, K
    Durand-Zaleski, I
    Souchet, T
    VALUE IN HEALTH, 2003, 6 (03) : 317 - 318
  • [42] Economic evaluation of losartan compared with atenolol in the treatment of hypertension with left ventricular hypertrophy: Cost-minimization analysis based on LIFE study
    Chevreul, K
    Durand-Zaleski, I
    Souchet, T
    VALUE IN HEALTH, 2003, 6 (06) : 666 - 666
  • [43] Cost-effectiveness of aliskiren added to losartan and optimal antihypertensive therapy in patients with hypertension, type 2 diabetes, and nephropathy by age
    Delea, Thomas E.
    Sofrygin, Oleg
    Palmer, James L.
    Annemans, Liev-En
    Lau, Helen
    Munk, Veronica C.
    Sung, Jennifer
    Charney, Alan
    Sullivan, Sean D.
    DIABETES, 2008, 57 : A137 - A137
  • [44] Comments on systematic review of clinical- and cost-effectiveness of candesartan and losartan in hypertension and heart failure
    Meredith, P. A.
    Jarvis, S. C.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (08) : 911 - 911
  • [45] Cost-Effectiveness of Team-Based Care for Hypertension
    Rao, Aditi S.
    Bryant, Kelsey B.
    Cohen, Laura P.
    Dandan, Nadine
    Kronish, Ian M.
    Barai, Nikita
    Fontil, Valy
    Zhang, Yiyi
    Moran, Andrew E.
    Bellows, Brandon K.
    CIRCULATION, 2022, 146
  • [46] An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings
    Palmer, AJ
    Annemans, L
    Roze, S
    Lamotte, M
    Rodby, RA
    Cordonnier, DJ
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (10) : 2059 - 2066
  • [47] Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial
    Steg, Philippe Gabriel
    Bhatt, Deepak L.
    James, Stefan K.
    Darlington, Oliver
    Hoskin, Louise
    Simon, Tabassome
    Fox, Kim M.
    Leiter, Lawrence A.
    Mehta, Shamir R.
    Harrington, Robert A.
    Himmelmann, Anders
    Ridderstrale, Wilhelm
    Andersson, Marielle
    Bueno, Hector
    De Luca, Leonardo
    Tank, Amarjeet
    Mellstrom, Carl
    McEwan, Phil
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 8 (08) : 777 - 785
  • [48] The Cost-effectiveness of a Specialist Depression Service For Resistant Depression: An Economic Evaluation Alongside a Clinical Trial
    Sampson, Christopher James
    James, Marilyn
    JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2015, 18 : S35 - S35
  • [49] The cost-effectiveness of early goal-directed therapy: an economic evaluation alongside the ARISE trial
    Higgins, Alisa M.
    Peake, Sandra L.
    Bellomo, Rinaldo A. O.
    Cooper, D. Jamie A. O.
    Delaney, Anthony
    Howe, Belinda D.
    Nichol, Alistair D.
    Webb, Steve A.
    Williams, Patricia J.
    Harris, Anthony H.
    CRITICAL CARE AND RESUSCITATION, 2021, 23 (03) : 329 - 336
  • [50] COST-EFFECTIVENESS OF PHARMACOLOGIC HYPERTENSION THERAPY: ECONOMIC ANALYSIS OF ARBS IN COLOMBIA
    Castro, D.
    Silva, C.
    Bohorquez-Nassar, C.
    Gomez, J. C.
    VALUE IN HEALTH, 2009, 12 (07) : A502 - A502
12345